Changing lives through medical technology

Lifecare develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers.

Regarding Preferential Rights Issue

The subscription period shall commence on 30 May 2024 at 09:00 (CEST) and expire on 13 June 2024 at 16:30 (CEST). The subscription period cannot be shortened, but the Board may extend the subscription period if this is required by law as a result of the publication of a supplement prospectus.

Information is available here


Lifecare licenses a nanosensor technology for medical use to other companies. We help to facilitate the production and sales of medical devices. Our technology has the potential to improve medical products by adding sensing functionalities to devices in all medical indications.

We believe people with diabetes deserve better than current devices.

Today, people with diabetes are dependent on painful and time-consuming glucose measurement procedures based on a more than 40-year-old technology.

Our aim is to help people with diabetes to live a normal life enabled by a glucose sensor at the size of a grain of rice – called Sencell – that continuously measures glucose levels for far longer time periods than currently existing devices.

Read more


Lifecare is dedicated to developing the next generation of miniaturized and implantable long-term sensors. We have a particular focus on diabetes and are dedicated towards helping the more than 500 million people living with diabetes. Lifecare AS is listed on Euronext Growth Oslo with ticker “LIFE”.

As of 31.12.2022 94,22 % of Lifecare’s share capital was held by Norwegian investors. 5,50 % were registered in the EU, whereas 0,27 % were registered outside the EU.

See top 10 shareholders Investor contact